Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers

Ovarian malignancies are a leading cause of cancer-related death for US women. High-grade serous ovarian carcinomas (HGSOCs), the most common ovarian cancer subtype, are aggressive tumors with poor outcomes. Mutations in TP53 are common in HGSOCs, with a subset resulting in p53 aggregation and misre...

Full description

Bibliographic Details
Main Authors: Adam Neal, Tiffany Lai, Tanya Singh, Neela Rahseparian, Tristan Grogan, David Elashoff, Peter Scott, Matteo Pellegrini, Sanaz Memarzadeh
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
ovarian cancer
p53
carboplatin resistance
combination therapy
in vitro organoid drug assay
Online Access:https://www.mdpi.com/2072-6694/13/23/5908

Internet

https://www.mdpi.com/2072-6694/13/23/5908

Similar Items